Alnylam announces filing for marketing authorization of onpattro in brazil for the treatment of hereditary attr amyloidosis with polyneuropathy

Alnylam announces filing for marketing authorization of onpattro® (patisiran) in brazil for the treatment of hereditary attr amyloidosis with polyneuropathy.alnylam pharmaceuticals - alnylam expects a decision from anvisa in first half of 2020.alnylam pharmaceuticals - submission of marketing authorization of onpattro (patisiran) made under accelerated regulatory pathway for rare diseases.
ALNY Ratings Summary
ALNY Quant Ranking